Merck Zostavax Shingles Vaccine Safe and Effective For Adults Over 60, Committee Says
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's Vaccines & Related Biological Products Advisory Committee said data do not support Merck's proposed indication for adults as young as 50 years.
You may also be interested in...
Zostavax Gets Nod For Younger Age Group, But Supply Issues Make Sales Boost Unlikely
Merck's ability to capitalize on FDA approval of the shingles vaccine in patients ages 50-59 years is questionable given ongoing supply constraints.
Zostavax Gets Nod For Younger Age Group, But Supply Issues Make Sales Boost Unlikely
Merck's ability to capitalize on FDA approval of the shingles vaccine in patients ages 50-59 years is questionable given ongoing supply constraints.
Merck’s Zostavax Shingles Vaccine Approved
FDA approved the herpes zoster vaccine for patients ages 60 years and older.